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Objective: The long-term administration of erythromycin (EM), clarithromycin (CAM) or azithromycin (AZM) has 
generally resulted in a favorable outcome for patients with diffuse panbronchiolitis (DPB) infected with mucoid 
Pseudomonas aeruginosa. To elucidate the mechanism involved, the influence of macrolides on mucoid alginate 
production by k? aeruginosa was investigated in vitro. 
Methods: The rnacrolides used in this study were EM with a ICmembered ring, AZM with a 15-membered ring, 
midecamycin (MDM) with a 16-membered ring, and CP-4305, which has had mycarose removed from MDM, The effects 
of macrolides on mucoid k? aeruginosa were investigated by quantitative assay of alginate production and inhibition of 
guanosine diphospho-D-mannose dehydrogenase activity. 
Results: After incubation with EM, AZM and CP-4305, the structural material of P aeruginosa biofilm was distorted, 
and the enzymatic activity of GDP-D-mannose dehydrogenase, the most important enzyme in mucoid alginate 
biosynthesis, was inhibited. However, these effects were not observed with the 16-membered macrolide MDM. 
Conciusions: The basic mechanism of clinical efficacy seen characteristically in 14- or 15-membered macrolides 
for patients with airway biofilm disease depends on the ability of such macrolides to inhibit alginate production by 
P aeruginosa. Furthermore, this suggests that the inhibitory effect observed with 14-, 15- and 16-membered macrolides 
may depend on the sugar chain connected with the macrolide ring. 
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INTRODUCTION 
It is well known that the bacteria that colonize mucous 
membranes or medical devices in nutrient-poor con- 
ditions often produce mucoid alginate (glycocalyx) 
around their bodies and form a bacterial biofilm [ 1-31. 
In this state, the biofilm bacteria are usually resistant 
to attack by antimicrobial agents [4-61 and host 
phagocytes [7,8]. Cystic fibrosis (CF) [9,10] and diffuse 
panbronchiolitis (DYB) [I I]  are typical diseases that 
show bacterial biofilm formation by the niucoid 
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alginate produced by Pseudomonas aeruginosa [12,13]. 
In 1987, the 10-year survival rate of DPB patients in 
Japan was only 12.4% for those colonized with mucoid 
I? aeruginosa but 73.1% for those without I? aeruginosa 
[14]. In the past 10 years, however, long-term admini- 
stration of erythromycin (EM) [15], clarithromycin 
(CAM) [16] or azithromycin (AZM) [17] as basic 
therapy has been used, and the prognosis of patients, 
including that of patients colonized with I! aeruginosa, 
has improved remarkably, reaching a 10-year survival 
rate of over 90%. This clinical efficacy of macrolides 
was not observed with 16-membered macrolides. O n  
the other hand, alginate facilitates bacterial adherence 
to lung tissue [18,19] and plays a pathogenic role in 
some diseases which are associated with persistent 
colonization with mucoid J? aevuginosa [7,8,20]. 
Against this background, the influence of macro- 
lides on niucoid alginate production by J? aeruginosa was 
examined in vitro. 
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METHODS 
Materials 
Mucoid I! aerclgrinosu PT-1578 (provided by Pfizer 
Pharmaceutical Inc., Tokyo), a niucoid clinical isolate, 
was used in this study. The strain was preincubated on 
heart infusion agar (Nissui Phariiiaceutical Co., Ltd, 
Tokyo) at  37°C. EM (Dainippon Pharmaceutical Co., 
Ltd, Osaka), AZM (Pfizer Pharmaceutical Inc.), 
niidecariiycin (MDM) (Meiji Seika Kaisha, Ltd., 
Tokyo) and CP-4305 (Meiji Seika Kaisha, Ltd, Tokyo) 
were used (Figure 1). All agents were dissolved in 
methanol, and methanol alone was used as the control 
in experiments. 
Determination of MlCs 
The minimum inhibitory concentrations (MICs) for 
the strain of each inacrolide were measured on 
Mueller-Hinton agar by the twofold dilution method. 
The inoculum was lo6 colony-forming units (CFU) 
per spot. 
In vitro formation of biofilm on membrane filters and effect 
of macrolides 
I! nevclgirzosa PT-1578 was suspended in biological saline 
(saline) to 10* CFU/mL, and 50 yL was put on poly- 
carbonate membrane filters with a pore size of 0.22 pin 
(Nihon Millipore Kogyo K. K., Tokyo) which were set 
on saline agar. Each membrane filter was incubated a t  
37 "C for 5 days. After confirmation of the presence of 
the bacterial biofilm by scanning electron microscopy, 
the menibrane filters were transferred into 2 niL of 
20% alginate-promoting (AP) medium 121 1 (100 mM 
monosodium glutamate, 100 iiiM sodium gluconate, 
7.5 mM NaH2PO4, 16.3 m M  KzHPO4, 10 mM 
MgS04.7H20) including 10 pg/mL of each macrolide, 
and then incubated at  37°C for 5 days. 
Quantitative analysis of alginate 
After suspending I! aerq inosa  PT-1578 in saline to 
lo2 CFU/mL, 100 yL of the solution was put on poly- 
carbonate membrane filters with a pore size of 0.22 pin 
(Millipore) set on 10% AP medium agar including each 
macrolide (final concentrations: 1 and 10 yg/~iiL). Each 
membrane filter was incubated at 37OC for 27 h, and 
then left at  room temperature for 18 h. The membrane 
filter with bacteria colonizing its surfaces was put into 
2 m L  of saline and vigorously stirred for 1 min. To 
remove the bacterial bodies, the sample obtained by the 
above method was centrifuged at 7000g for 10 min. 
desosanimose I b"3 / 
Erythromycin 
CP-4305 
Figure 1 Structures of macrolides used in this study. 
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The supernatant was extracted and used for the deter- 
mination of alginate. 
Quantitative analysis of alginate was performed by 
the Bitter-Muir method [22]. The sample in 0.5 mL 
was gently added to 2 niL of 0.95% Na2B407.10HzO 
in 98% H2S04 in an ice bath, and, after mixing, the 
mixture was heated at 100°C for 10 min and cooled in 
an ice bath. After stirring with 0.1 mL of 0.125% 
carbazole in ethanol, the mixture was heated at 100°C 
for 15 min again. When the mixture was cooled in an 
ice bath to room temperature, the optical density was 
measured at 530 nni with a spectrophotometer (model 
100-60; Hitachi-Seisakusho, Tokyo). The quantity of 
alginate was calculated on the basis of a standard curve 
made with D( +)-glucuronolactone. 
Data were from triplicate determinations and were 
expressed as means and the standard deviation. 
Purification of guanosine diphospho-0-mannose 
dehydrogenase 
Bacterial cells were grown aerobically in 500 mL of AP 
medium a t  37°C for 18 h. The culture was used to 
inoculate 6.5 L of AP medium, and cells were then 
grown aerobically at 37°C for 5 h. The cells were 
harvested by centrifugation at 10 000g at 4°C for 
30 min. Approximately 6 g wet weight of the cell 
pellet was washed once with 200 mL of Dulbecco's 
phosphate-buffered saline (PBS) (Gibco Laboratories, 
Grand Island, NY) and resuspended in 10 mL of 
sonication buffer containing 10 mM 3-(N-morpho- 
linopropanesulfonic acid) (MOPS), 0.5 niM phenyl- 
niethylsulfonyl fluoride (PMSF) and 2 m M  dithio- 
threitol (DTT) a t  pH 7.0. The cells were disrupted by 
ultrasonic disruptor model UR-200P (Tomy Seikou 
Co., Ltd, Tokyo). Cell debris was removed by centri- 
fugation at 20 000g at 4°C for 1 h. This supernatant 
was treated with protamine sulfate to a 1% final 
concentration and immediately centrifuged at 20 000g 
at 4°C for 1 h to remove DNA. The final supernatant 
was filtered with a membrane filter ofpore size 0.45 pm 
(Toyo Roshi Kaisha, Ltd, Tokyo) and then dialyzed 
against 500 mL of elution buffer containing 50 mM 
Tris-HC1, 1 mh4 PMSF and 5 mM D T T  at pH 7.5 at 
4°C overnight. The crude extract was applied to an 
elution buffer-equilibrated DEAE TOYOPAL 650s 
(Tosoh Ltd, Tokyo) column (1 x 10 cm) and fraction- 
ated by elution with a 0-0.2 M linear gradient of NaCl 
in elution buffer. 
Effects of macrolides on guanosine diphospho-0-mannose 
dehydrogenase activity 
GDP-mannose dehydrogenase activity was measured 
by Preiss's method [23]. That is, the enzymatic activity 
of GDP-mannose dehydrogenase was assayed by optical 
density at 340 mi at 30 "C using a spectrophotometer. 
A GDP-inannose dehydrogenase fraction sample of 
50 pL was obtained from a total volume of 500 pL of 
substrate solution containing 50 mM Tris-HC1, 10 niM 
MgCL, 1 mM NAD and 1 mM GDP-D-mannose at 
pH 7.5. N o  endogenous dehydrogenase activity was 
detected in the GDP-mannose dehydrogenase fraction 
sample, as indicated by the absence of reduction of 
NAD when GDP-mannose was omitted from the 
incubation mixture. One unit of enzymatic activity was 
defined as that which reduced 1 pmol of NAD per niin 
under the specified conditions. 
The interaction between GDP-mannose dehydro- 
genase activity and niacrolides was investigated by the 
following methods. Macrolides dissolved in methanol 
were added to the GDP-mannose dehydrogenase 
fraction saniple and it was incubated at 30OC for 5 min. 
At a 0.25-1.5 niM final concentration of macrolides, 
GDP-mannose dehydrogenase activity was measured in 
comparison with methanol solution as the control. 
Statistical analysis 
Student's t-test was used for statistical analysis of data. 
The niacrolides used in this study were EM with a 14- 
membered ring, AZM with a 15-membered ring, 
MDM with a 16-membered ring, and CP-4305, a 
derivative of MDM (Figure I). In CP-4305, which has 
had inycarose removed from MDM, mycaminose 
appears on the surface. In EM and AZM, deso- 
saminose, which is similar to inycaminose, occurs on 
the surface. From this point of view, CP-4305 is similar 
to EM and AZM. These niacrolides were chosen to 
analyze the mechanism of action against I? nerugitzosa 
biofilni. 
MlCs of macrolides for bacteria 
The MICs of EM, AZM, CP-4305 and MDM for 
F! aeruginasa PT-1578 were 50, 200, >400 and 
>400 pg/mL, respectively. 
Effects of macrolides on the structure of biofilm 
The biofilm model of P aeruginosa PT-1578 on the 
surfaces of membrane filters was observed by scan- 
ning electron microscopy after 5 days of treatment 
with 10 pg of inacrolides per mL (Figure 2). In the 
control, membranous structures covering the colonies 
with glycocalyx were preserved for 5 days (a). After 
incubation with 10 pg/mL EM (b), AZM (c) and 
CP-4305 (d), reduction of the glycocalyx and eradica- 
tion of the nieinbranous structures were observed. 
However, neither the significant decrease in glycocalyx 
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nor eradication of the membranous structure was 
observed after incubation with 10 pg/iiiL MDM (e). 
Effects of macrolides on alginate productian 
Alginate production by lo8 CFU of I? ueruginosa is 
shown quantitatively (Figure 3 ) .  Compared with the 
control, the production of alginate was inhibited by 
incubation with EM, AZM and CP-4305 in a dose- 
dependent manner, but no inhibitory effect was 
observed with MDM. Thus, the production of alh' ma te  
was inhibited only by the Agents that exerted a 
deleterious effect on biofilm. 
Figure 2 Changes in structure of bacterial biofilms after treatment with 10 pg of each macrolide pcr mL. (a) Control 
(without drugs); (b) EM; (c) AZM; (d) C1'-4305; (e) MDM. 
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Figure 5 Inhibitory effect of macrolides on GDP-mannose 
dehydrogenase activity. Assay conditions are described in 
the text. The control was incubated with methanol only. 
The vertical axis indicates remaining GDP-mannose 
dehydrogenase activity, with the value of the control 
assumed to be 100%. Data are means of two independent 
experiments and standard errors. 
Figure 3 Influence of macrolide agents on alginate 
production from I? aeruginosa. Data are from triplicate 
determinations and are expressed as means and standard 
deviation. NS=non-significant; *P<0.01. 
0 60 80 20 40 
Number of fraction 
Figure 4 Elution profile of GDP-mannose dehydrogenase 
following fractionation of crude extract of P aevuginosa via 
anion exchange chromatography. The dotted line represents 
the NaCl gradient (0-0.2 M). The top line represents the 
distribution of protein. The bottom line represents the 
distribution of CDP-mannose dehydrogenase activity. 
elution profile of GDP-mannose dehydrogenase follow- 
ing fractionation is shown in Figure 4. GDP-mannose 
dehydrogenase activity was detected as the only peak; 
no other peaks were detected. The GDP-mannose 
dehydrogenase fractions were used to investigate the 
effect of macrolides on  GDP-mannose dehydrogenase 
activity. 
GDP-mannose dehydrogenase activities in the 
controls were AOD 0.538 and AOD 0.514. The value 
of the control was assumed to be loo%, and each value 
was compared with this. After the enzyme and the 
macrolides had been incubated at 30OC for 5 niin, 
500 mL of the substrate solution was added. A dose- 
dependent reduction in GDP-mannose dehydrogenase 
activity was observed after incubation with EM, AZM 
and CP-4305, but not M D M  (Figure 5). CP-4305 was 
the most potent inhibitor of the three agents, followed 
by AZM. 
Biofilm bacteria usually show resistance to antimicrobial 
Effects of macrolides on GDP-mannose dehydrogenase agents, but the killing of l? aeruginosa inside biofdm was 
activity obtained by the combined use of ciprofloxacin (CPFX) 
The cells were disrupted by sonic vibration, and and CAM [11,24] or AZM [11,24] rather than by 
the supernatant was obtained by centrifugation. GDP- CPFX alone. This was also observed with EM, but 
niannose dehydrogenase was separated by anion not with josaniycin [25]. A possible interpretation 
exchange Chromatography from this supernatant. The is that 14- or 15-membered niacrolides facilitate the 
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Figure 6 Pathway of alginate synthesis by 1? nevzginosa. Abbreviations: F6P, fructose 6-phosphatc; M6P, mannose 6- 
phosphate; MlP, mannose 1-phosphate; GDP-Man, GDP-mannose; GDP-Man A, GDP-mannuronic acid; PMI, 
phosphornannose isomerase; PMM, phosphomannoniutasc; GMf: guanosine diphospho-D-mannosc pyrophosphorylace; 
GMD, guanosine diphospho-D-mannose dehydrogenasc. The remaining steps of alginate synthesis are polymerization, 
epimerization, acetylation and export. The u/gA gene encodes a PMI-GMP enzyme, algC encodes PMM, and algD encodes 
GMD. 
penetration of the bacterial biofilm by CPFX, which 
would then eliminate the bacteria inside the biofilm. 
Thus, the anti-P aevuginosa action of CPFX and the 
anti-alginate action of such macrolides depend on their 
combined effects. In this investigation, incubation of P 
aeruginosa biofilnis with EM, AZM and (3-4305 for 5 
days resulted in destruction of biofilni substance, but 
this did not occur with MDM. The findings indicate 
that such macrolides express some sort of anti-alginate 
action, even if they have no ability to kill P aevuginosa. 
The important point that we wish to emphasize is that 
the anti-alginate action of macrolides is a key point 
in understanding the mechanism of clinical efficacy 
seen in patients with DPB and other airway biofilm 
diseases, and probably in patients with CF, because the 
immune reaction induced by mucoid alginate plays an 
important role in the pathogenesis and clinical mani- 
festations of DPB [26] and CF [27-291. In this paper, 
the 14-membered macrolide EM as well as the 15- 
membered macrolide AZM inhibited alginate pro- 
duction by mucoid P aevugiaosa in a dose-dependent 
manner, but no inhibitory effect was observed with the 
16-membered macrolide MDM. 
The alginate biosynthetic pathway in mucoid 
J? aevuginosa has been demonstrated to involve phos- 
phomannose isomerase (PMI) [30,31], phosphoman- 
nomutase (PMM) [30,31], guanosine diphospho- 
D-mannose pyrophosphorylase (GMP) [30,31], 
GDP-mannose dehydrogenase [30J 11, epimerase 
[32,33], polymerase [34] and acetylase [35] (Figure 6). 
The first four enzymes (PMI, PMM, GMP and GDP- 
mannose dehydrogenase) of alginate biosynthesis are 
detected in mucoid I! aeruginosa but not in the 
non-mucoid form [36]. The enzymatic activity of 
GDP-niannose dehydrogenase is significantly higher 
than that of other enzymes in mucoid strains [37]. 
GDP-mannose dehydrogenase encoded by the ulgD 
gene is thought to be especially important in the 
alginate biosynthetic pathway. 
EM and AZM inhibited the enzymatic activity of 
GDP-mannose dehydrogenase in a dose-dependent 
manner, but this inhibition was not observed with 
the 36-membered MDM. This may help to clarify 
the characteristics of 14- and 15-membered macro- 
lides. In this study, the anti-GDP-mannose dehydro- 
genase effect began to appear at a concentration of 
0.5 mM (EM, 367 pg/niL; AZM, 393 pg/mL; MDM, 
407 pg/mL; (2-4305, 306 pg/mL) of macrolides. The 
concentration was unexpectedly higher than that 
indicated by clinical experience. O n  the other hand, 
the enzymatic activity of GDP-mannose dehydro- 
genase in a single bacterium, even of a mucoid strain, 
is below the limit of detection. In crude enzyme from 
disrupted cells, 8 mL of cells in the stationary phase of 
growth was needed to detect the GDP-mannose 
dehydrogenase activity. This may be the reason why a 
higher concentration of macrolide was needed to show 
the inhibitory effect on GDP-niannose dehydrogenase 
activity in our experiments. No inhibition was ob- 
served at such a high concentration of MDM. In terms 
of clinical efficacy, a much lower dose of macrolide may 
be useful. 
Another interesting result obtained in this study 
was that a similar inhibitory effect on both alginate 
production and GDP-mannose dehydrogenase activity 
was observed with CP-4305, which was derived by 
excising mycarose from the 16-membered macrolide 
MDM. The evidence indicates that the inhibitory 
effect could be seen when the terminal sugar was 
removed, with exposure of mycaminose, even in a 16- 
membered macrolide. This suggests that the inhibitory 
effect observed with 14- and 15-membered niacrolides 
is not based on the structural specificity of the macro- 
lide ring per se, but depends on the sugar chain 
connected with position 5 of the ring, and that an 
adequate inhibitory effect can be obtained if the end 
sugar chain is removed, even in a 16-membered 
macrolide. Thus the efficacy of 14- and 15-membered 
macrolides in airway biofilm disease may depend on 
such structural factors. 
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